• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Syncor to distribute PerImmune MoAb

Article

Radiopharmacy firm Syncor International of Woodland Hills, CA, has signed an agreement for worldwide distribution of monoclonal antibody-based imaging and therapy agents under development by PerImmune of Rockville, MD. The deal includes HumaSPECT/CR, a

Radiopharmacy firm Syncor International of Woodland Hills, CA, has signed an agreement for worldwide distribution of monoclonal antibody-based imaging and therapy agents under development by PerImmune of Rockville, MD. The deal includes HumaSPECT/CR, a human monoclonal antibody for the diagnosis and staging of colorectal cancer that PerImmune is developing. Syncor also announced that it has completed its acquisition of the iodine-123 business of Golden Pharmaceuticals of Golden, CO (SCAN 2/19/97).

Recent Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.